Method for the treatment of pains or pyrexia due to the accentuation of central nerve

• US 4,649,133 A
• Filed: 09/26/1985
• Issued: 03/10/1987
• Est. Priority Date: 05/26/1978
• Status: Expired due to Fees

• Current Assignee: Kureha Kagaku Kogyo Kabushiki Kaisha
• Original Assignee: Kureha Kagaku Kogyo Kabushiki Kaisha
• Inventors: Matsunaga, Kenichi, Fujii, Takayoshi, Ikuzawa, Masanori, Ando, Takao, Yoshikumi, Chikao, Ohhara, Minoru, Ohmura, Yoshio, Hirose, Fumio
• Primary Examiner(s): Brown, Johnnie R.
• Application Number:
  US06/780,211
• Time in Patent Office: 530 Days
• Field of Search: 536/22, 536/18.7, 514/42, 514/23, 514/62
• US Class Current: 514/42
• CPC Class Codes: C07H 15/203 Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems

Abstract

Disclosed is a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of central nerve or tumor, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoic acid-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

Claims

1. A method for the treatment of pains due to the accentuation of central nerve, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoate-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein said pharmaceutically acceptable salt is the sodium salt.

3. The method of claim 1 comprising orally administering said pharmaceutically acceptable salt in an amount of about 1 to 500 mg per kg per day.

4. The method of claim 1 comprising parenterally administering said pharmaceutically acceptable salt in an amount of about 0.01 to about 200 mg per kg per day.

5. A method for the treatment of pyrexia due to the accentuation of central nerve, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoate-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 wherein said pharmaceutically acceptable salt is the sodium salt.

7. The method of claim 5 comprising orally administering said pharmaceutically acceptable salt in an amount of about 1 to 500 mg per kg per day.

8. The method of claim 5 comprising parenterally administering said pharmaceutically acceptable salt in an amount of about 0.01 to about 200 mg per kg per day.